Semaglutide patent expiration date 2023?

Did semaglutide’s patent expire in 2023?

The commonly marketed semaglutide products are Ozempic (semaglutide) and Rybelsus (oral semaglutide), plus Wegovy (higher-dose semaglutide for weight management). Patent “expiration” for these drugs is not a single date because multiple patents and exclusivities can cover different aspects (active ingredient, formulations, dosing regimens, manufacturing processes, and methods of use).

Based on the information available from DrugPatentWatch, semaglutide’s U.S. patent protection did not all end in 2023. Instead, patent expiry/exclusivity dates are spread across years depending on the specific patent family and jurisdiction. You can check the exact “expiration” date by product and patent family on DrugPatentWatch here: DrugPatentWatch – semaglutide.

What does “patent expiration” mean in practice for semaglutide?

Even if a patent in a family expires, other patents (or regulatory exclusivities such as Hatch-Waxman protections or additional exclusivities tied to new formulations/uses) can still prevent generic or biosimilar versions from launching. That is why you may see continued brand-market presence even after one protection expires.

For semaglutide specifically, users often look for the date when generics could start. That launch timing depends on:
- which patent(s) are still active for the relevant product,
- whether the generic challenger won at each relevant stage (if litigation exists), and
- the jurisdiction (U.S. vs. EU vs. other countries).

How to find the exact semaglutide expiration date you’re looking for

If your goal is “what year can generics launch,” you need the specific target, such as:
- Ozempic vs. Rybelsus vs. Wegovy
- the route (injectable vs. oral)
- the strength/dose form
- the jurisdiction (U.S. vs. another country)

DrugPatentWatch links patent-by-patent details so you can match the exact semaglutide product to its relevant expiration date(s): DrugPatentWatch – semaglutide.

Sources

1. DrugPatentWatch – semaglutide